147 related articles for article (PubMed ID: 15342407)
21. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
[TBL] [Abstract][Full Text] [Related]
22. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action.
Zalipsky S; Saad M; Kiwan R; Ber E; Yu N; Minko T
J Drug Target; 2007; 15(7-8):518-30. PubMed ID: 17671898
[TBL] [Abstract][Full Text] [Related]
24. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense.
Minko T; Dharap SS; Fabbricatore AT
Cancer Detect Prev; 2003; 27(3):193-202. PubMed ID: 12787726
[TBL] [Abstract][Full Text] [Related]
25. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
[TBL] [Abstract][Full Text] [Related]
27. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
28. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421
[TBL] [Abstract][Full Text] [Related]
29. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
30. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
Zangemeister-Wittke U; Schenker T; Luedke GH; Stahel RA
Br J Cancer; 1998 Oct; 78(8):1035-42. PubMed ID: 9792147
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
32. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
33. Meloxicam increases intracellular accumulation of doxorubicin via downregulation of multidrug resistance-associated protein 1 (MRP1) in A549 cells.
Chen SF; Zhang ZY; Zhang JL
Genet Mol Res; 2015 Nov; 14(4):14548-60. PubMed ID: 26600514
[TBL] [Abstract][Full Text] [Related]
34. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
[TBL] [Abstract][Full Text] [Related]
35. MRP- and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro.
Khodadadian M; Leroux ME; Auzenne E; Ghosh SC; Farquhar D; Evans R; Spohn W; Zou Y; Klostergaard J
Lung Cancer; 2009 Oct; 66(1):48-57. PubMed ID: 19195736
[TBL] [Abstract][Full Text] [Related]
36. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE
Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776
[TBL] [Abstract][Full Text] [Related]
37. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
38. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.
Campling BG; Young LC; Baer KA; Lam YM; Deeley RG; Cole SP; Gerlach JH
Clin Cancer Res; 1997 Jan; 3(1):115-22. PubMed ID: 9815546
[TBL] [Abstract][Full Text] [Related]
39. [Drug resistance reversal of HL-60/ADR cells by simultaneous suppression of XIAP and MRP].
Wang XF; Wang C; Qin YW; Yan SK; Gao YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1110-5. PubMed ID: 17204174
[TBL] [Abstract][Full Text] [Related]
40. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
